Focused on the commercialization and development of abuse-resistant opioid formulations.
Location: United States, Pennsylvania, Radnor Township
Employees: 11-50
Total raised: $34.3M
Founded date: 1995
Investors 2
| Date | Name | Website |
| - | Omega Fund... | omegafunds... |
| - | Hercules C... | htgc.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 16.09.2013 | - | $20M | - |
| 07.05.2012 | Series B | $14.3M | - |
Mentions in press and media 7
| Date | Title | Description |
| 11.07.2017 | Egalet Closes $30 Million Public Equity Offering | Egalet Corporation (Nasdaq: EGLT), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain and other conditions, today announced the closing of its previously ann... |
| 16.09.2013 | Egalet Closes up to $20M Funding | Egalet Ltd., a London, UK- and Malvern, PA-based specialty pharmaceutical company developing and planning to commercialize abuse-deterrent oral products for the treatment of pain and other indications, closed a financing of up to $20m. The ... |
| 13.09.2013 | Egalet scores up to $20M for next-gen pain drug as FDA aims to block abuse | Egalet has found more venture capital support for development of next-generation opioid treatments. The Malvern, PA-based developer has taken in $10 million of a potential $20 million round led by previous backer Index Ventures. The company... |
| 08.05.2012 | Abuse-resistant opioid maker hires pharma veteran as CEO, raises $14 million | Egalet’s erosion technology means the drug is gradually absorbed and is part of an effort by some drugmakers to address the costly problem of prescription drug abuse. Promoted Covid-19’s terrible toll on diabetes patients. What can be done?... |
| 07.05.2012 | Egalet Announces $14.3M Series B Financing | MALVERN, PA, Privately held specialty pharmaceutical company focused on developing safe, effective and abuse-resistant medications, announced today that it has raised $14.3 million in a Series B financing round. >> Click here for m... |
| 07.05.2012 | Egalet Raises $14.3M in Series B Financing | Egalet Ltd., a Værløse , Denmark-based specialty pharmaceutical company focused on developing abuse-resistant medications, has raised $14.3m in a Series B financing. Backers included CLS Capital and existing investors Atlas Venture, Omega F... |
| - | Abuse-resistant opioid maker hires pharma veteran as CEO, raises $14 million | A drugmaker specializing in extended release, abuse-resistant drug delivery for opioids has raised more than $14 million in series B financing to advance its lead products through clinical trials. It has also hired a pharmaceutical veteran ... |